| Project/Area Number |
17K11127
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高倉 正博 金沢医科大学, 医学部, 准教授 (20313661)
小中 弘之 金沢大学, 医学系, 協力研究員 (40334768)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | エクソソーム / 泌尿器癌 / 去勢抵抗性前立腺癌 / 泌尿器科癌 / 癌 / 遺伝子 / 蛋白質 |
|---|
| Outline of Final Research Achievements |
We tried to find out a novel metastatic biomarkers of urological cancers using liquid biopsy as a repeatable and less invasive method. Adenovirus vector with GFP and hTERT promotor could detect cancer cells mixed in human blood samples; however, it needed more than 100 cells /ml to detect them, indicating low paformance for clinical use as it was. Micro RNA analysis in exosome from supernatant of protate cancer cells reveled that miR124 might contribute to metastasis of castration-resistant prostate cancer.
|
| Academic Significance and Societal Importance of the Research Achievements |
泌尿器癌においては、CTC検出の実用化にはまだ大きなハードルが存在するものの、去勢抵抗性前立腺癌では本研究で得られたexosomeに内包されたmicro RNAのプロファイルをもとに、新規バイオマーカーを開発できる可能性が示唆された。
|
